Celldex Therapeutics Inc
$ 39.05
3.61%
04 Aug - close price
- Market Cap 2,958,366,000 USD
- Current Price $ 39.05
- High / Low $ 39.34 / 37.54
- Stock P/E N/A
- Book Value 6.85
- EPS -4.27
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.49 %
- 52 Week High 40.30
- 52 Week Low 19.72
About
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Analyst Target Price
$57.07
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-25 | 2025-11-10 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-06 | 2024-08-08 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-08 |
| Reported EPS | -1.18 | -1.22 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 |
| Estimated EPS | -1.13 | -1 | -0.89 | -0.86 | -0.74 | -0.7146 | -0.67 | -0.59 | -0.67 | -0.74 | -0.66 | -0.66 |
| Surprise | -0.05 | -0.22 | -0.12 | 0.01 | -0.07 | 0.0046 | 0.03 | 0.05 | 0.11 | -0.09 | -0.15 | 0.01 |
| Surprise Percentage | -4.4248% | -22% | -13.4831% | 1.1628% | -9.4595% | 0.6437% | 4.4776% | 8.4746% | 16.4179% | -12.1622% | -22.7273% | 1.5152% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLDX
2026-07-31 22:13:26
Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared to direct peers based on price-to-book ratio, it appears expensive against the broader US biotech industry, prompting investors to assess whether the market is overly cautious or conservative about its potential.
2026-07-31 09:40:18
This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high and low P/E values. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not been disclosed by the company.
2026-07-29 08:41:08
This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a significant year-over-year decrease in quarterly revenue and net profit. The analysis breaks down various financial dimensions including cash and cash equivalents, total assets, total liabilities, and free cash flow.
2026-07-28 05:10:37
This article provides a comprehensive stock analysis of Celldex Therapeutics Inc (CLDX) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company's fundamentals are considered healthy with significant growth potential, and it is deemed fairly valued within the Biotechnology & Medical Research industry. Analysts have rated CLDX as a Buy, with expectations for the stock price to trend upward in the medium term.
2026-07-27 13:10:08
This article details the shareholder structure of Celldex Therapeutics Inc (CLDX), listing major shareholders such as Wellington Management Company, LLP and BlackRock Institutional Trust Company, N.A., along with their respective holdings and proportions. It also breaks down shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Additionally, the article identifies related ETFs that hold CLDX stock.
2026-07-26 05:40:00
Celldex Therapeutics Inc (CLDX) has an earnings forecast score of 8.50, ranking 106th in the Biotechnology & Medical Research industry, with an average price target of $53.00. Analysts largely recommend a "Buy" for CLDX, with 16 analysts providing ratings. The company's expected revenue for the next quarter is $954.44K, and EPS for the next quarter is projected at USD -1.06.
